Show simple item record

dc.contributor.authorTan, Angel
dc.contributor.authorSimovic, Spomenka
dc.contributor.authorDavey, Andrew K
dc.contributor.authorRades, Thomas
dc.contributor.authorPrestidge, Clive A
dc.date.accessioned2017-05-03T16:01:14Z
dc.date.available2017-05-03T16:01:14Z
dc.date.issued2009
dc.date.modified2011-02-11T08:03:11Z
dc.identifier.issn0168-3659
dc.identifier.doi10.1016/j.jconrel.2008.10.014
dc.identifier.urihttp://hdl.handle.net/10072/36093
dc.description.abstractA silica-lipid hybrid (SLH) microcapsule system for oral delivery of poorly water-soluble drugs is reported for the first time. For the model drug celecoxib (CEL), SLH microcapsules composed of medium-chain triglycerides, lecithin and silica nanoparticles; with an internal porous matrix structure, were shown to offer several physicochemical and biopharmaceutical advantages in comparison with unmodified drug, lipid emulsion, dry emulsion and the commercial product, CelebrexDSC and XRD analyses confirmed non-crystalline CEL in SLH microcapsules and verified medium term physical stability. Dissolution under sink conditions revealed a 2- to 5-fold increase in dissolution efficiencies (%DE) and significantly reduced t50% (= 50-fold) for CEL formulated as SLH microcapsules. Orally dosed in vivo studies in rats demonstrated superior pharmacokinetics for SLH microcapsules. Specifically, the fasted-state bioavailability (F) was statistically higher (p < 0.05) than for aqueous suspension, lipid solution, o/w emulsion and a maltodextrin-stabilised dry emulsion, and was greater than for CelebrexSLHs showed the highest maximum plasma concentration (Cmax) among all tested formulations (p < 0.05). Linear correlations were observed between %DE and the pharmacokinetic parameters (F and Cmax). It is postulated that SLH microcapsules improve CEL oral absorption via dissolution enhancement, potentially in conjunction with other unexplored mechanisms, hence offering the possibility of dose reduction for improved therapeutic efficacy and cost-effectiveness of poorly soluble drugs.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.languageEnglish
dc.language.isoeng
dc.publisherElsevier
dc.publisher.placeNetherlands
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom62
dc.relation.ispartofpageto70
dc.relation.ispartofissue1
dc.relation.ispartofjournalJournal of Controlled Release
dc.relation.ispartofvolume134
dc.rights.retentionY
dc.subject.fieldofresearchBiomedical engineering
dc.subject.fieldofresearchChemical engineering
dc.subject.fieldofresearchPharmacology and pharmaceutical sciences
dc.subject.fieldofresearchPharmaceutical sciences
dc.subject.fieldofresearchcode4003
dc.subject.fieldofresearchcode4004
dc.subject.fieldofresearchcode3214
dc.subject.fieldofresearchcode321405
dc.titleSilica-lipid hybrid (SLH) microcapsules: a novel oral delivery system for poorly soluble drugs
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.date.issued2010
gro.hasfulltextNo Full Text
gro.griffith.authorDavey, Andrew


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record